NVCR News and Press, NovoCure Limited From 02/28/22

NovoCure's revenue growth has slowed down in recent quarters. COVID-19 is having an impact, but Optune in GBM is also in a more mature stage with 35% market penetration in existing markets. Longer term, there are significant growth opportunities in the GBM market, driven by device...

Professor Palti is the inventor of Tumor Treating Fields, electric fields that disrupt cancer cell division The Israel Prize is regarded as the State of Israel’s highest cultural honor Novocure (NASDAQ: NVCR) today announced that Yoram Palti, Novocure’s...

Todd Longsworth’s work was foundational to the growth of Novocure in becoming a global oncology company Barak Ben Arye has been appointed to General Counsel, effective April 1 Novocure (NASDAQ: NVCR) today announced that Todd Longsworth, General Counsel, has r...

Image source: The Motley Fool. Novocure (NASDAQ: NVCR) Q4 2021 Earnings Call Feb 24, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Novocure (NVCR) Q4 2021 Earnings Call Transcript

NovoCure Limited (NVCR) Q4 2021 Earnings Conference Call February 24, 2022 8:00 AM ET Company Participants Ingrid Goldberg – Vice President of Finance and Investor Relations Bill Doyle – Executive Chairman Asaf Danziger – Chief Executive Officer Ashley Cordova – Ch...

The following slide deck was published by NovoCure Limited in conjunction with their 2021 Q4 earnings call. For further details see: NovoCure Limited 2021 Q4 - Results - Earnings Call Presentation

NovoCure press release (NASDAQ:NVCR): Q4 GAAP EPS of -$0.25 misses by $0.15. Revenue of $133.21M (-7.5% Y/Y) misses by $1.28M. The company expects to achieve active patient growth between 2% to 5% in 2022, in-line with the growth rate experienced in the fourth quarter of 2021. Longer term, th...

Tumor Treating Fields dually activates the STING and AIM2 pro-inflammatory signaling pathways that drive early anti-tumor immune responses Novocure (NASDAQ: NVCR) today announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment wi...

Full year 2021 net revenues of $535 million, an increase of 8% year-over-year Invested record $201 million in 2021 in research and development initiatives intended to advance Tumor Treating Fields science and technology Novocure (NASDAQ: NVCR) today reported financia...

NovoCure (NASDAQ:NVCR) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$0.10 (-350.0% Y/Y) and the consensus Revenue Estimate is $134.49M (-6.6% Y/Y). Over the last 1 year, NVCR has beaten EPS estimates 25% of the tim...